Compare SUVEN LIFE with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES PFIZER SUVEN LIFESCIENCES/
PFIZER
 
P/E (TTM) x 18.4 32.5 56.8% View Chart
P/BV x 3.7 5.4 68.6% View Chart
Dividend Yield % 0.6 0.6 90.1%  

Financials

 SUVEN LIFESCIENCES   PFIZER
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
PFIZER
Mar-18
SUVEN LIFESCIENCES/
PFIZER
5-Yr Chart
Click to enlarge
High Rs3382,365 14.3%   
Low Rs1691,625 10.4%   
Sales per share (Unadj.) Rs52.1430.3 12.1%  
Earnings per share (Unadj.) Rs6.878.7 8.7%  
Cash flow per share (Unadj.) Rs8.693.2 9.2%  
Dividends per share (Unadj.) Rs1.5020.00 7.5%  
Dividend yield (eoy) %0.61.0 59.0%  
Book value per share (Unadj.) Rs65.3586.5 11.1%  
Shares outstanding (eoy) m127.2845.75 278.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.94.6 104.9%   
Avg P/E ratio x37.125.3 146.4%  
P/CF ratio (eoy) x29.621.4 138.2%  
Price / Book Value ratio x3.93.4 114.2%  
Dividend payout %22.025.4 86.4%   
Avg Mkt Cap Rs m32,27291,271 35.4%   
No. of employees `0001.12.6 41.1%   
Total wages/salary Rs m6613,143 21.0%   
Avg. sales/employee Rs Th6,132.27,484.8 81.9%   
Avg. wages/employee Rs Th611.11,195.0 51.1%   
Avg. net profit/employee Rs Th803.51,369.1 58.7%   
INCOME DATA
Net Sales Rs m6,63519,685 33.7%  
Other income Rs m2421,143 21.2%   
Total revenues Rs m6,87720,828 33.0%   
Gross profit Rs m1,6045,003 32.1%  
Depreciation Rs m221663 33.4%   
Interest Rs m384 897.6%   
Profit before tax Rs m1,5875,479 29.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7181,878 38.2%   
Profit after tax Rs m8693,601 24.1%  
Gross profit margin %24.225.4 95.1%  
Effective tax rate %45.234.3 131.9%   
Net profit margin %13.118.3 71.6%  
BALANCE SHEET DATA
Current assets Rs m6,23224,167 25.8%   
Current liabilities Rs m1,4909,544 15.6%   
Net working cap to sales %71.574.3 96.2%  
Current ratio x4.22.5 165.2%  
Inventory Days Days8655 156.9%  
Debtors Days Days8329 287.8%  
Net fixed assets Rs m4,0439,514 42.5%   
Share capital Rs m127458 27.8%   
"Free" reserves Rs m8,18326,375 31.0%   
Net worth Rs m8,31026,832 31.0%   
Long term debt Rs m1825 71.2%   
Total assets Rs m10,38936,900 28.2%  
Interest coverage x43.11,305.5 3.3%   
Debt to equity ratio x00 229.9%  
Sales to assets ratio x0.60.5 119.7%   
Return on assets %8.79.8 89.4%  
Return on equity %10.513.4 78.0%  
Return on capital %19.520.4 95.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62222 25,097.2%   
Fx outflow Rs m1,7991,489 120.9%   
Net fx Rs m3,822-1,466 -260.7%   
CASH FLOW
From Operations Rs m3563,318 10.7%  
From Investments Rs m-279-2,383 11.7%  
From Financial Activity Rs m-225-1,104 20.4%  
Net Cashflow Rs m-148-169 88.0%  

Share Holding

Indian Promoters % 63.4 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 0.0 7.5 -  
FIIs % 0.0 4.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 23.7 154.0%  
Shareholders   37,287 85,207 43.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   NOVARTIS  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ASTRAZENECA PHARMA  

Compare SUVEN LIFESCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 292 Points Higher; Automobile and Metal Stocks Witness Buying(Closing)

After opening the day marginally higher, Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Oct 15, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS